T

Talis Biomedical Corp
NASDAQ:TLIS

Watchlist Manager
Talis Biomedical Corp
NASDAQ:TLIS
Watchlist
Price: 2.84 USD Market Closed
Market Cap: 90m USD

Net Margin
Talis Biomedical Corp

-12 506.4%
Current
-3 708%
Average
1.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-12 506.4%
=
Net Income
-51m
/
Revenue
408k

Net Margin Across Competitors

No Stocks Found

Talis Biomedical Corp
Glance View

Market Cap
90m USD
Industry
Health Care

Talis Biomedical Corp. develops and commercialize innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company is headquartered in Menlo Park, California. The company went IPO on 2021-02-12. (Talis) Is engaged in developing molecular diagnostic tests for infectious diseases at the point of care. The firm is focused on developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions. Talis is developing the Talis One platform, a cloud-enabled molecular diagnostic platform. The Talis One platform comprises a compact instrument, single-use test cartridges and software, including a central cloud database, which work together and are designed to provide central laboratory levels of accuracy. The platform is designed for use in non-laboratory settings, such as physicians’ offices, hospital emergency departments, urgent care clinics, ambulatory surgery centers, assisted living facilities, and cancer treatment and dialysis centers. The firm is also developing Talis One tests for respiratory infections, infections related to women’s health and sexually transmitted infections.

TLIS Intrinsic Value
Not Available
T
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-12 506.4%
=
Net Income
-51m
/
Revenue
408k
What is the Net Margin of Talis Biomedical Corp?

Based on Talis Biomedical Corp's most recent financial statements, the company has Net Margin of -12 506.4%.

Back to Top